Snipd home pageGet the app
public
The IMID Forum chevron_right

Author Interview: Mark Russell

Jul 7, 2023
30:21
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
1
Introduction
00:00 • 2min
chevron_right
2
The Impact of Oral Surveillance on the Jack Market
02:16 • 4min
chevron_right
3
The Limitations of RCT Data
05:46 • 2min
chevron_right
4
The Importance of Sensitivity in Oral Surveillance
07:37 • 2min
chevron_right
5
The Role of Topha in Non-Melanoma Skin Cancer
09:58 • 3min
chevron_right
6
The Absolute Risk of Melanoma
12:59 • 2min
chevron_right
7
Jax Causes Cancer and Non-Melanoma Skin Cancer
14:59 • 2min
chevron_right
8
The Effects of TNFs on Malignancy
17:21 • 2min
chevron_right
9
The Effect of Dose on Malignancy Rates
19:37 • 3min
chevron_right
10
The Effects of Jacks on Non-Melanoma Skin Cancer
22:35 • 4min
chevron_right
11
The Effects of Jack Inhibitors on Malignancy
26:34 • 2min
chevron_right
12
Jacks in the Hail Jacks Top of Ground
28:34 • 2min
chevron_right
Professor Peter Nash from the Griffith University in Brisbane, is joined by Dr Mark Russell, a clinical research fellow at the Centre for Rheumatic Diseases, King’s College London to discuss his recent paper 'JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications'.
HomeTop podcastsPopular guests